Key Figures of the Group

show table
2013 2014 2015 20161 2017
Business
Sales€ million 1,830.4 2,120.1 2,601.7 2,903.2 2,996.3
EBITDA2€ million 373.1 464.5 572.2 625.2 630.3
EBIT2€ million 283.1 337.9 395.2 422.3 431.6
EBIT margin2in % 15.5 15.9 15.2 14.5 14.4
Net income2€ million 172.3 211.6 246.8 265.5 270.3
Balance sheet total (as of December 31)€ million 2,210.4 3,999.8 4,183.8 4,752.7 4,674.6
Capital ratio (as of December 31)in % 43.0 35.8 38.0 36.4 37.8
Investments (without M & A)€ million 70.7 101.3 147.2 168.4 204.9
Net debt (incl. pension provisions and similar obligations) /
EBITDA (as of December 31)2
ratio
2.0 3.2 2.8 3.1 3.0
Research and development expenses2€ million 127.0 138.9 169.6 186.0 196.4
Operating cash flow€ million 274.8 343.2 375.2 338.8 396.2
 
Capital Market
Shares issued as of reporting datemillions 118.2 129.8 129.8 129.8 129.8
Share price at end of fiscal year (Xetra® closing price)in € 33.50 50.13 61.33 57.83 71.62
Market capitalization at end of fiscal year€ million 3,958.8 6,507.5 7,961.4 7,507.1 9,297.2
Earnings per share2in € 1.46 1.69 1.90 2.05 2.08
Dividend per sharein € 0.70 0.75 0.80 0.85 0.883
OUR FIVE GOAL DIMENSIONS 2016 2017 Goals
 
Business
Organic sales growthin % 8 6 5—7CAGR by 2020
EBITDA marginin % 21.5 21.0 19–22by 2020
Share of sales for emerging marketsin % 43 44 >502020
 
Footprint 4
Reduction in greenhouse gas emissions (Scope 1+2)in % –5.4 –7.8 –5 p.a.by 2020
Reduction in chemical oxygen demand in wastewaterin % –17.3 –15.3 –4 p.a.by 2020
Reduction in sensitive wastein % +0.9 –9.7 –4 p.a.by 2020
 
Innovation
Sales from new product developments 5in % 15.5 15.9 >10
 
Sourcing
Main suppliers rated according to sustainability criteria 6in % 86 80 100by 2020
Traceability of strategic raw materialsin % 95 100by 2020
Primary palm oil derivatives from certified sustainable sources 7in % 63 100by 2020
 
Care
Women in the first management levelin % 15 21 17by 2020
Women in the second management levelin % 19 44 22by 2020
Accident frequencyMAQ8 3.8 4.7 < 2.0by 2020
1
2016 restated for finalized Nutraceutix Purchase Price Allocation
2
Figures for 2014 and 2016 normalized for transaction and integration costs as well as one-off valuation effects related to business combinations
3
proposal
4
All figures relative to the value created
5
Market launch in the past three years
6
Based on procurement volume
7
Primary raw materials and derivatives from palm oil sourced according to Symrise’s “Palm Oil Policy”
8
MAQ = Number of accidents (> 1 lost day) x 1 million/number of working hours